MoCA Cognition

We are thrilled to announce the opening of our new European office in the Netherlands! The MoCA Test, recognized globally as the leading tool for early detection of cognitive impairment, continues to be an essential resource for healthcare professionals and researchers. With the launch of MoCA Cognition EU, we are strengthening our relationships with care providers, researchers, institutions, and partners across Europe.   Under the leadership of Murray Gillies, PhD, our Vice President for Science and Innovation, this new office marks a significant milestone in our mission to expand access and innovation in cognitive assessment. Dr. Gillies received his PhD from the University of Glasgow and brings with him years of experience in digital healthcare, including senior roles within Philips Healthcare and Biogen Digital Health. His background includes SaMD engineering of specialized digital tools used for diagnosing and treating neurological diseases such as Alzheimer's as well as product strategy and development. As Vice President for Science and Innovation at MoCA cognition, he is responsible for the creation of new digital tools and connecting to the European ecosystem.   

Thank you for all the support in the #Netherlands! The High Tech Campus of #Eindhoven is a great new home as we expand to the EU.

Will you be attending CTAD Clinical Trials on Alzheimer's Disease in #Madrid? We’re excited to reconnect with many friends and collaborators and look forward to meeting new ones! If you’ll be there, feel free to reach out to us here or email [email protected] to organize a meeting. Let’s make the most of this great opportunity at #CTAD24!

Our CEO and MoCA creator, Dr. Ziad Nasreddine is proud to be participating in #LausanneXI. It is an honor to connect with Mr. George Vradenburg, Chairman of Davos Alzheimer's Collaborative and Convener of the CEOi - Global CEO Initiative on Alzheimer's Disease This annual event is organized by the CEOi, founded in 2013, is an organization of private-sector leaders who have joined together to provide business leadership in the fight against #Alzheimers. The CEOi believes that, during this era of aging populations, it will take visionary, coordinated, goal-oriented leadership of public and private leaders working together to solve our greatest challenges.

#AAIC24 Poster presentation: "A Usability Study of MoCA XpressO". Meet MoCA creator Dr. Ziad Nasreddine at poster 600 or visit our booth 1325

Wonderful to be back for #AAIC24! So many familiar faces and great to meet many of you for the first time. If you're around, tag us on Linkedin to get a MoCA notebook or mug :)

We’re proud to share that the MoCA test has been recognized as a valuable Real-World Evidence (RWE) tool in the fight against Alzheimer's disease.  This recognition, highlighted in the latest publication in the Alzheimer's & Dementia journal, underscores MoCA’s effectiveness in capturing clinically relevant data outside of traditional clinical trials. Real-World Evidence is crucial for understanding how treatments perform in everyday settings. As a widely used cognitive screening tool, MoCA's role in RWE will enhance our ability to monitor cognitive health and tailor interventions more effectively. A heartfelt thank you to all researchers and healthcare professionals dedicated to advancing #Alzheimers care. Together, we’re paving the way for better patient outcomes and a deeper understanding of #cognitivehealth. https://lnkd.in/eRfFcbQE

Please join us on May 23 for a panel discussion, 𝗘𝗻𝗿𝗼𝗹𝗹𝗶𝗻𝗴 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝘀, 𝗠𝗮𝗶𝗻𝘁𝗮𝗶𝗻𝗶𝗻𝗴 𝗘𝗻𝗴𝗮𝗴𝗲𝗺𝗲𝗻𝘁, 𝗮𝗻𝗱 𝗧𝗿𝗮𝗰𝗸𝗶𝗻𝗴 𝗖𝗼𝗴𝗻𝗶𝘁𝗶𝗼𝗻 𝗶𝗻 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹𝘀, primarily focused on decentralized trials in #Alzheimers. The event will be highly relevant for healthcare professionals and clinical trial coordinators aiming to better support patient recruitment and improve engagement remotely. 👉 𝗔𝘁𝘁𝗲𝗻𝗱 𝘁𝗵𝗲 𝘄𝗲𝗯𝗶𝗻𝗮𝗿: https://lnkd.in/ejFWRd43 The webinar will be presented in collaboration with uMotif and our panelists include: 🧠 𝗔𝘂𝗱𝗿𝗲𝘆 𝗚𝗮𝗯𝗲𝗹𝗹𝗲, MD, PhD Professor of Neurology, Cognitive Neurologist and Doctor in Neurosciences, Montpellier Excellence Center of Neurodegenerative Disorders 🧠 Bruce Hellman, Chief Patient Officer and Co-Founder, uMotif 🧠 Murray Gillies, PhD, Vice President for Science and Innovation, MoCA Cognition #healthcare #AlzheimersDisease #dementia #clinicaltrial #brainhealth #earlydetection

We are delighted to announce an upcoming panel discussion (May 23) to be presented in collaboration with uMotif: "𝗘𝗻𝗿𝗼𝗹𝗹𝗶𝗻𝗴 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝘀, 𝗠𝗮𝗶𝗻𝘁𝗮𝗶𝗻𝗶𝗻𝗴 𝗘𝗻𝗴𝗮𝗴𝗲𝗺𝗲𝗻𝘁, 𝗮𝗻𝗱 𝗧𝗿𝗮𝗰𝗸𝗶𝗻𝗴 𝗖𝗼𝗴𝗻𝗶𝘁𝗶𝗼𝗻 𝗶𝗻 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹𝘀" will delve into the evolving challenges and strategies in trials involving #cognition — particularly those related to #AlzheimersDisease — and how the #clinician can better support the recruitment process. 👉 𝗔𝘁𝘁𝗲𝗻𝗱 𝘁𝗵𝗲 𝘄𝗲𝗯𝗶𝗻𝗮𝗿: https://lnkd.in/ejFWRd43 Our panelists for the event: 🧠 𝗔𝘂𝗱𝗿𝗲𝘆 𝗚𝗮𝗯𝗲𝗹𝗹𝗲, MD, PhD Professor of Neurology, Cognitive Neurologist and Doctor in Neurosciences, Montpellier Excellence Center of Neurodegenerative Disorders   🧠 Bruce Hellman, Chief Patient Officer and Co-Founder, uMotif   🧠 Murray Gillies, PhD, Vice President for Science and Innovation, MoCA Cognition

MoCA creator, Ziad Nasreddine MD participated in an insightful panel discussion covering practical considerations in the interpretation of cognitive assessments alongside a patient's history, including the key red flags that suggest #AlzheimersDisease is the likely underlying pathology. The experts also consider the next steps following a clinical assessment, including the use of #neuroimaging, and recent advancements in #biomarker technology.